The global antibody market size is estimated to be worth around 266.83 billion in 2024. The total market value of the antibodies sector is anticipated to increase at a CAGR of 8.1% from 2024 to 2033. Furthermore, it is anticipated that the market for antibodies will reach US$ 581.42 billion by 2034. The total market growth of the antibodies sector represented in absolute dollars is US$ 315 billion.
| Report Attribute | Details |
|---|---|
| Antibody Market Size (2024) | US$ 266.83 billion |
| Market Anticipated Forecast Value (2034) | US$ 581.42 billion |
| Market Projected Growth Rate (2024 to 2034) | 8.1% CAGR |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The global antibody market was valued at US$ 131.47 billion in 2019. The market overview of antibody drugs progressed at an annual rate of 12.5% between 2019 and 2023. The overall market value was about US$ 236.86 billion by 2023.
| Attributes | Details |
|---|---|
| Antibody Market Value (2019) | US$ 131.47 billion |
| Market Revenue (2023) | US$ 236.86 billion |
| Market Historical Growth Rate (CAGR 2019 to 2023) | 12.5% CAGR |
Principal Consultant
Research and Development Activities Impact Antibodies Sales Outlook
A surge in research and development activities among pharmaceutical market leaders to develop economical and effective antibodies is driving growth opportunities for diagnostic specialty antibody suppliers.
In February 2021, Abingdon Health collaborated with Abcam to explore opportunities for their service and portfolio expansion which includes Abcam's reagent portfolio and Abingdon Health's rapid test contract development and manufacturing services.
Rising cases of multiple sclerosis and Parkinson's disease among the older population is a key factor fueling the demand for antibodies. There is an urgency to develop personalized and cheap medicines, advanced therapeutics, advanced genetic engineering technology, and novel and effective treatments in middle-income countries.
In 2021, Berkeley Lights, a digital cell biology company, joined hands with Genovac, an antibody discovery company, to readily access the right antibodies in the shortest amount of time with the help of modern technology.
Increasing Production of Bio-similar Antibodies is Driving Demand
Biosimilar antibodies are experiencing heavy demand as they are inexpensive in comparison with human monoclonal antibodies, and they have very few side effects. In 2020, Johnson and Johnson reported US$ 3.75 Billion achieved through the sales of Remicade. According to Pfizer, Inflectra, the biosimilar competitor of Remicade, generated US$ 659 million in 2020.
USA Food and Drug Administration (FDA) approved a biosimilar of Remicade called Avsola in December 2019 and is now eligible for producing biologics products all over the world. Increasing demand for biosimilar antibodies in the treatment of rheumatoid arthritis, along with a high patient acceptance rate, is anticipated to boost the market growth for antibodies.
One of the leaders in prescription medicines, Pfizer, received EU approval for biosimilar antibody therapeutics Amsparity for Crohn’s disease, psoriasis, and psoriatic arthritis in February 2020. Elevated new drug approval rates and products in clinical trials in pharmaceutical companies are anticipated to further drive the market in the upcoming years.
The table below mentions the countries that are expected to witness higher growth opportunities in this market.
| Regional Market Comparison | CAGR (2024 to 2034) |
|---|---|
| United States | 9.6% |
| Germany | 9.4% |
| United Kingdom | 10.1% |
| India | 9.5% |
| China | 6.5% |
The United States therapeutic antibodies market is poised to advance at a rate of 10.1% per year till 2034.
Consumption of antibody products in the United Kingdom is projected to rise at a rate of 10.1% during the forecast years.
The antibodies industry in China is projected to thrive at a CAGR of 5.8% through the projected years.
Sales of antibodies in Germany are anticipated to increase at a rate of 9.4% from 2024 to 2034.
Demand for antibodies in India is expected to rise at a rate of 9.5% per year between 2024 and 2034.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Based on product type, the monoclonal antibodies market segment is estimated to account for 95% of the market share in 2024.
| Attributes | Details |
|---|---|
| Top Product Type or Segment | Monoclonal Antibodies |
| Total Market Share in 2024 | 95% |
Based on disease indication, the use of antibodies for treating cancer is expected to account for 57% of the total sales in 2024.
| Attributes | Details |
|---|---|
| Top Disease Indication Type or Segment | Cancer |
| Total Market Share in 2024 | 57% |
Leading market players are working towards developing new antibodies to remain competitive in the present market. They are also researching to create long-acting antibody drugs to reduce healthcare costs and attract chronic patients.
In order to gain a competitive edge in the antibody testing market, key players are developing oral and noninvasive treatments using antibodies to treat chronic ailments. Strategic mergers and acquisitions for portfolio expansion are in the cards as well.
Future market players should concentrate on acquiring additional money through financing rounds to broaden their research and company scope. New businesses are looking into how to leverage cutting-edge technologies to streamline the creation of therapeutic antibodies, including nanobodies and monoclonal antibodies.
Recent Developments in the Global Antibody Market
On June 11, 2021, Novartis published its new Phase II data of an investigational oral treatment iptacopan, developed for treating paroxysmal nocturnal hemoglobinuria (PNH). The study indicated that during 12 weeks of iptacopan monotherapy treatment, no unexpected safety issues were reported which led to rapid and durable transfusion-free improvement of hemoglobin levels in the majority of patients.
In August 2020, Johnson & Johnson entered into a final agreement to acquire Momenta Pharmaceuticals Inc. for around US$ 6.5 Billion. Momenta Pharmaceuticals Inc. is a market leader in developing novel therapies for immune-mediated diseases.
The acquisition may allow the Janssen Pharmaceutical Companies of Johnson & Johnson to expand its product portfolio in immune-mediated diseases while driving growth opportunities through expansion into autoantibody-driven disease.
Leading pharmaceutical company Sanofi announced in March 2022 that it will collaborate with IGM Biosciences to research, produce, and market six novel immunoglobulin M antibody agonists. Sanofi has agreed to approximately US$ 6 billion in possible milestone payments through this agreement.
| Attribute | Details |
|---|---|
| Estimated Market Size (2024) | US$ 266.83 billion |
| Projected Market Size (2034) | US$ 581.42 billion |
| Anticipated Growth Rate (2024 to 2034) | 8.1% |
| Forecast Period | 2024 to 2034 |
| Historical Data Available for | 2019 to 2023 |
| Market Analysis | US$ million or billion for Value and Units for Volume |
| Key Regions Covered | North America; Latin America; Europe; Middle East & Africa (MEA); East Asia; South Asia and Oceania |
| Key Countries Covered | United States, Canada, Brazil, Mexico, Germany, Spain, Italy, France, United Kingdom, Russia, China, India, Australia & New Zealand, GCC Countries, and South Africa |
| Key Segments Covered | By Product Type, By Disease Indication, By End Use Verticals, and By Region |
| Key Companies Profiled | Novartis AG; F. Hoffmann-La Roche AG; Johnson & Johnson; Takeda Pharmaceutical Company Limited; Amgen Inc. |
| Report Coverage | Market Forecast, Company Share Analysis, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, and Strategic Growth Initiatives |
| Customization & Pricing | Available upon Request |
The global antibody market is estimated to be around US$ 266.83 billion in 2024.
The global antibody market is to grow at 8.1% during the forecast period.
The global antibody market is predicted to be valued at US$ 581.42 billion by 2034.
The global antibody market was valued at US$ 131.47 billion in 2019.
The United Kingdom to witness 10.1% CAGR in sales of antibodies through 2034.
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2019 to 2023 and Forecast, 2024 to 2034
4.1. Historical Market Size Value (US$ Million) Analysis, 2019 to 2023
4.2. Current and Future Market Size Value (US$ Million) Projections, 2024 to 2034
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Disease Indication
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Disease Indication, 2019 to 2023
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Disease Indication, 2024 to 2034
5.3.1. Cardiovascular Diseases
5.3.2. CNS Disorders
5.3.3. Cancer
5.3.4. Autoimmune Disorders
5.4. Y-o-Y Growth Trend Analysis By Disease Indication, 2019 to 2023
5.5. Absolute $ Opportunity Analysis By Disease Indication, 2024 to 2034
6. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Product Type
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By Product Type, 2019 to 2023
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Product Type, 2024 to 2034
6.3.1. Monoclonal Antibodies
6.3.2. Polyclonal Antibodies
6.3.3. Antibody-Drug Complexes
6.4. Y-o-Y Growth Trend Analysis By Product Type, 2019 to 2023
6.5. Absolute $ Opportunity Analysis By Product Type, 2024 to 2034
7. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By End User
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ Million) Analysis By End User, 2019 to 2023
7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End User, 2024 to 2034
7.3.1. Hospitals
7.3.2. Long-Term Care Facilities
7.3.3. Research Institutes
7.4. Y-o-Y Growth Trend Analysis By End User, 2019 to 2023
7.5. Absolute $ Opportunity Analysis By End User, 2024 to 2034
8. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Region
8.1. Introduction
8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2019 to 2023
8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2024 to 2034
8.3.1. North America
8.3.2. Latin America
8.3.3. Western Europe
8.3.4. Eastern Europe
8.3.5. South Asia and Pacific
8.3.6. East Asia
8.3.7. Middle East and Africa
8.4. Market Attractiveness Analysis By Region
9. North America Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023
9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034
9.2.1. By Country
9.2.1.1. USA
9.2.1.2. Canada
9.2.2. By Disease Indication
9.2.3. By Product Type
9.2.4. By End User
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Disease Indication
9.3.3. By Product Type
9.3.4. By End User
9.4. Key Takeaways
10. Latin America Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034
10.2.1. By Country
10.2.1.1. Brazil
10.2.1.2. Mexico
10.2.1.3. Rest of Latin America
10.2.2. By Disease Indication
10.2.3. By Product Type
10.2.4. By End User
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Disease Indication
10.3.3. By Product Type
10.3.4. By End User
10.4. Key Takeaways
11. Western Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034
11.2.1. By Country
11.2.1.1. Germany
11.2.1.2. UK
11.2.1.3. France
11.2.1.4. Spain
11.2.1.5. Italy
11.2.1.6. Rest of Western Europe
11.2.2. By Disease Indication
11.2.3. By Product Type
11.2.4. By End User
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Disease Indication
11.3.3. By Product Type
11.3.4. By End User
11.4. Key Takeaways
12. Eastern Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034
12.2.1. By Country
12.2.1.1. Poland
12.2.1.2. Russia
12.2.1.3. Czech Republic
12.2.1.4. Romania
12.2.1.5. Rest of Eastern Europe
12.2.2. By Disease Indication
12.2.3. By Product Type
12.2.4. By End User
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Disease Indication
12.3.3. By Product Type
12.3.4. By End User
12.4. Key Takeaways
13. South Asia and Pacific Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023
13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034
13.2.1. By Country
13.2.1.1. India
13.2.1.2. Bangladesh
13.2.1.3. Australia
13.2.1.4. New Zealand
13.2.1.5. Rest of South Asia and Pacific
13.2.2. By Disease Indication
13.2.3. By Product Type
13.2.4. By End User
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Disease Indication
13.3.3. By Product Type
13.3.4. By End User
13.4. Key Takeaways
14. East Asia Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023
14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034
14.2.1. By Country
14.2.1.1. China
14.2.1.2. Japan
14.2.1.3. South Korea
14.2.2. By Disease Indication
14.2.3. By Product Type
14.2.4. By End User
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Disease Indication
14.3.3. By Product Type
14.3.4. By End User
14.4. Key Takeaways
15. Middle East and Africa Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Country
15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2019 to 2023
15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2024 to 2034
15.2.1. By Country
15.2.1.1. GCC Countries
15.2.1.2. South Africa
15.2.1.3. Israel
15.2.1.4. Rest of MEA
15.2.2. By Disease Indication
15.2.3. By Product Type
15.2.4. By End User
15.3. Market Attractiveness Analysis
15.3.1. By Country
15.3.2. By Disease Indication
15.3.3. By Product Type
15.3.4. By End User
15.4. Key Takeaways
16. Key Countries Market Analysis
16.1. USA
16.1.1. Market Share Analysis, 2023
16.1.1.1. By Disease Indication
16.1.1.2. By Product Type
16.1.1.3. By End User
16.2. Canada
16.2.1. Market Share Analysis, 2023
16.2.1.1. By Disease Indication
16.2.1.2. By Product Type
16.2.1.3. By End User
16.3. Brazil
16.3.1. Market Share Analysis, 2023
16.3.1.1. By Disease Indication
16.3.1.2. By Product Type
16.3.1.3. By End User
16.4. Mexico
16.4.1. Market Share Analysis, 2023
16.4.1.1. By Disease Indication
16.4.1.2. By Product Type
16.4.1.3. By End User
16.5. Germany
16.5.1. Market Share Analysis, 2023
16.5.1.1. By Disease Indication
16.5.1.2. By Product Type
16.5.1.3. By End User
16.6. UK
16.6.1. Market Share Analysis, 2023
16.6.1.1. By Disease Indication
16.6.1.2. By Product Type
16.6.1.3. By End User
16.7. France
16.7.1. Market Share Analysis, 2023
16.7.1.1. By Disease Indication
16.7.1.2. By Product Type
16.7.1.3. By End User
16.8. Spain
16.8.1. Market Share Analysis, 2023
16.8.1.1. By Disease Indication
16.8.1.2. By Product Type
16.8.1.3. By End User
16.9. Italy
16.9.1. Market Share Analysis, 2023
16.9.1.1. By Disease Indication
16.9.1.2. By Product Type
16.9.1.3. By End User
16.10. Poland
16.10.1. Market Share Analysis, 2023
16.10.1.1. By Disease Indication
16.10.1.2. By Product Type
16.10.1.3. By End User
16.11. Russia
16.11.1. Market Share Analysis, 2023
16.11.1.1. By Disease Indication
16.11.1.2. By Product Type
16.11.1.3. By End User
16.12. Czech Republic
16.12.1. Market Share Analysis, 2023
16.12.1.1. By Disease Indication
16.12.1.2. By Product Type
16.12.1.3. By End User
16.13. Romania
16.13.1. Market Share Analysis, 2023
16.13.1.1. By Disease Indication
16.13.1.2. By Product Type
16.13.1.3. By End User
16.14. India
16.14.1. Market Share Analysis, 2023
16.14.1.1. By Disease Indication
16.14.1.2. By Product Type
16.14.1.3. By End User
16.15. Bangladesh
16.15.1. Market Share Analysis, 2023
16.15.1.1. By Disease Indication
16.15.1.2. By Product Type
16.15.1.3. By End User
16.16. Australia
16.16.1. Market Share Analysis, 2023
16.16.1.1. By Disease Indication
16.16.1.2. By Product Type
16.16.1.3. By End User
16.17. New Zealand
16.17.1. Market Share Analysis, 2023
16.17.1.1. By Disease Indication
16.17.1.2. By Product Type
16.17.1.3. By End User
16.18. China
16.18.1. Market Share Analysis, 2023
16.18.1.1. By Disease Indication
16.18.1.2. By Product Type
16.18.1.3. By End User
16.19. Japan
16.19.1. Market Share Analysis, 2023
16.19.1.1. By Disease Indication
16.19.1.2. By Product Type
16.19.1.3. By End User
16.20. South Korea
16.20.1. Market Share Analysis, 2023
16.20.1.1. By Disease Indication
16.20.1.2. By Product Type
16.20.1.3. By End User
16.21. GCC Countries
16.21.1. Market Share Analysis, 2023
16.21.1.1. By Disease Indication
16.21.1.2. By Product Type
16.21.1.3. By End User
16.22. South Africa
16.22.1. Market Share Analysis, 2023
16.22.1.1. By Disease Indication
16.22.1.2. By Product Type
16.22.1.3. By End User
16.23. Israel
16.23.1. Market Share Analysis, 2023
16.23.1.1. By Disease Indication
16.23.1.2. By Product Type
16.23.1.3. By End User
17. Market Structure Analysis
17.1. Competition Dashboard
17.2. Competition Benchmarking
17.3. Market Share Analysis of Top Players
17.3.1. By Regional
17.3.2. By Disease Indication
17.3.3. By Product Type
17.3.4. By End User
18. Competition Analysis
18.1. Competition Deep Dive
18.1.1. Novartis AG
18.1.1.1. Overview
18.1.1.2. Product Portfolio
18.1.1.3. Profitability by Market Segments
18.1.1.4. Sales Footprint
18.1.1.5. Strategy Overview
18.1.1.5.1. Marketing Strategy
18.1.2. F. Hoffmann-La Roche Ltd.
18.1.2.1. Overview
18.1.2.2. Product Portfolio
18.1.2.3. Profitability by Market Segments
18.1.2.4. Sales Footprint
18.1.2.5. Strategy Overview
18.1.2.5.1. Marketing Strategy
18.1.3. Johnson & Johnson Services, Inc
18.1.3.1. Overview
18.1.3.2. Product Portfolio
18.1.3.3. Profitability by Market Segments
18.1.3.4. Sales Footprint
18.1.3.5. Strategy Overview
18.1.3.5.1. Marketing Strategy
18.1.4. Takeda Pharmaceutical Company Limited
18.1.4.1. Overview
18.1.4.2. Product Portfolio
18.1.4.3. Profitability by Market Segments
18.1.4.4. Sales Footprint
18.1.4.5. Strategy Overview
18.1.4.5.1. Marketing Strategy
18.1.5. Amgen Inc
18.1.5.1. Overview
18.1.5.2. Product Portfolio
18.1.5.3. Profitability by Market Segments
18.1.5.4. Sales Footprint
18.1.5.5. Strategy Overview
18.1.5.5.1. Marketing Strategy
18.1.6. Biogen Inc
18.1.6.1. Overview
18.1.6.2. Product Portfolio
18.1.6.3. Profitability by Market Segments
18.1.6.4. Sales Footprint
18.1.6.5. Strategy Overview
18.1.6.5.1. Marketing Strategy
18.1.7. Bristol-Myers Squibb Company
18.1.7.1. Overview
18.1.7.2. Product Portfolio
18.1.7.3. Profitability by Market Segments
18.1.7.4. Sales Footprint
18.1.7.5. Strategy Overview
18.1.7.5.1. Marketing Strategy
18.1.8. AbbVie Inc
18.1.8.1. Overview
18.1.8.2. Product Portfolio
18.1.8.3. Profitability by Market Segments
18.1.8.4. Sales Footprint
18.1.8.5. Strategy Overview
18.1.8.5.1. Marketing Strategy
18.1.9. Sanofi
18.1.9.1. Overview
18.1.9.2. Product Portfolio
18.1.9.3. Profitability by Market Segments
18.1.9.4. Sales Footprint
18.1.9.5. Strategy Overview
18.1.9.5.1. Marketing Strategy
18.1.10. Kyowa Kirin Co., Ltd
18.1.10.1. Overview
18.1.10.2. Product Portfolio
18.1.10.3. Profitability by Market Segments
18.1.10.4. Sales Footprint
18.1.10.5. Strategy Overview
18.1.10.5.1. Marketing Strategy
18.1.11. Iovance Biotherapeutics, Inc
18.1.11.1. Overview
18.1.11.2. Product Portfolio
18.1.11.3. Profitability by Market Segments
18.1.11.4. Sales Footprint
18.1.11.5. Strategy Overview
18.1.11.5.1. Marketing Strategy
19. Assumptions & Acronyms Used
20. Research Methodology
Explore Healthcare Insights
View Reports
Antibody Market
